{"brief_title": "DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis", "brief_summary": "This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.", "condition": ["Post Menopausal Osteoporosis"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["ibandronate [Bonviva/Boniva]", "ibandronate [Bonviva/Boniva]", "ibandronate [Bonviva/Boniva]"], "description": ["2mg iv every 2 months", "2.5mg po daily", "3mg iv every 3 months"], "arm_group_label": ["1", "2", "3"], "criteria": "Inclusion Criteria: - women 55-80 years of age; - post-menopausal for >=5 years; - ambulatory. Exclusion Criteria: - malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed); - breast cancer within the previous 20 years; - allergy to bisphosphonates; - previous treatment with an intravenous bisphosphonate at any time; - previous treatment with an oral bisphosphonate within the last 6 months, >1 month of treatment within the last year, or >3 months of treatment within the last 2 years.", "gender": "Female", "minimum_age": "55 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "mesh_term": ["Osteoporosis", "Osteoporosis, Postmenopausal", "Ibandronic acid", "Diphosphonates"], "id": "NCT00048074"}